Drug-induced Osteoporosis: Mechanisms and Clinical Implications

被引：190
作者：
Mazziotti, Gherardo
Canalis, Ernesto [2 ,3 ]
Giustina, Andrea [1 ]
机构：
[1] Univ Brescia, Dept Med & Surg Sci, Serv Endocrinol, I-25018 Montichiari, Italy
[2] St Francis Hosp & Med Ctr, Dept Res, Hartford, CT 06105 USA
[3] Univ Connecticut, Sch Med, Farmington, CT USA
来源：
AMERICAN JOURNAL OF MEDICINE | 2010年 / 123卷 / 10期
关键词：
Drugs; Fractures; Osteoporosis; Secondary osteoporosis; ANDROGEN-DEPRIVATION THERAPY; BONE-MINERAL DENSITY; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; THYROID-STIMULATING HORMONE; RANDOMIZED CONTROLLED-TRIAL; PROSTATE-CANCER; POSTMENOPAUSAL WOMEN; BREAST-CANCER; FRACTURE RISK; MEDROXYPROGESTERONE ACETATE;
D O I：
10.1016/j.amjmed.2010.02.028
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Drug-induced osteoporosis is common and has a significant impact on the prognosis of patients suffering from chronic debilitating diseases. Glucocorticoids are the drugs causing osteoporotic fractures most frequently, but osteoporosis with fractures is observed also in women treated with aromatase inhibitors for breast cancer, in men receiving anti-androgen therapy for prostate cancer, in postmenopausal women treated with high doses of thyroxine, and in men and women treated with thiazolinediones for type 2 diabetes mellitus. Bone loss with fractures also occurs in patients treated with drugs targeting the immune system, such as calcineurin inhibitors, antiretroviral drugs, selective inhibitors of serotonin reuptake, anticonvulsants, loop diuretics, heparin, oral anticoagulants, and proton pump inhibitors. (C) 2010 Elsevier Inc. All rights reserved. The American Journal of Medicine (2010) 123, 877-884
引用
收藏
页码：877 / 884
页数：8
相关论文
共 75 条
[1]   Mapping the prescriptiome to fractures in men-a national analysis of prescription history and fracture risk [J].
Abrahamsen, B. ;
Brixen, K. .
OSTEOPOROSIS INTERNATIONAL, 2009, 20 (04) :585-597
[2]   Incidence and risk factors for low trauma fractures in men with prostate cancer [J].
Ahlborg, Henrik G. ;
Nguyen, Nguyen D. ;
Center, Jacqueline R. ;
Eisman, John A. ;
Nguyen, Tuan V. .
BONE, 2008, 43 (03) :556-560
[3]   The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: A meta-regression [J].
Amin, S ;
Lavalley, MP ;
Simms, RW ;
Felson, DT .
JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 (08) :1512-1526
[4]   High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: A cross-sectional outpatient study [J].
Angeli, Alberto ;
Guglielmi, Giuseppe ;
Dovio, Andrea ;
Capelli, Giovanni ;
de Feo, Daniela ;
Giannini, Sandro ;
Giorgino, Ruben ;
Moro, Luigi ;
Giustina, Andrea .
BONE, 2006, 39 (02) :253-259
[5]   Risk for fracture in women with low serum levels of thyroid-stimulating hormone [J].
Bauer, DC ;
Ettinger, B ;
Nevitt, MC ;
Stone, KL .
ANNALS OF INTERNAL MEDICINE, 2001, 134 (07) :561-568
[6]   The clinical significance of subclinical thyroid dysfunction [J].
Biondi, Bernadette ;
Cooper, David S. .
ENDOCRINE REVIEWS, 2008, 29 (01) :76-131
[7]   Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review [J].
Brown, Todd T. ;
Qaqish, Roula B. .
AIDS, 2006, 20 (17) :2165-2174
[8]   Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole [J].
Brufsky, Adam ;
Bundred, Nigel ;
Coleman, Robert ;
Lambert-Falls, Rosemary ;
Mena, Raul ;
Hadji, Peyman ;
Jin, Lixian ;
Schenk, Nora ;
Ericson, Solveig ;
Perez, Edith A. .
ONCOLOGIST, 2008, 13 (05) :503-514
[9]   Glucocorticoid-induced osteoporosis: pathophysiology and therapy [J].
Canalis, E. ;
Mazziotti, G. ;
Giustina, A. ;
Bilezikian, J. P. .
OSTEOPOROSIS INTERNATIONAL, 2007, 18 (10) :1319-1328
[10]   Mechanisms of anabolic therapies for osteoporosis [J].
Canalis, Ernesto ;
Giustina, Andrea ;
Bilezikian, John P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (09) :905-916
12345678